Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
206 Results for "
Peptide E
" in MedChemExpress (MCE) Product Catalog:
Products (206)
206 Results for "Peptide E" in MCE Product Catalog:
Cat. No.: HY-P3874
CAS No.: 78355-50-7
Target:
Research Areas:
9
9 Cited Publications
Synonyms: T-DXd (solution); DS-8201 (solution); DS-8201a (solution)
9
9 Cited Publications
Synonyms: T-DXd; DS-8201; DS-8201a
5
5 Cited Publications
Cat. No.: HY-P2136
CAS No.: 878009-24-6
Target:
Research Areas:
4
4 Cited Publications
Cat. No.: HY-P1122
CAS No.: 83602-39-5
Target:
Research Areas:
3
3 Cited Publications
Cat. No.: HY-100566
Purity: 99.24%
Target:
Research Areas:
SuO-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the peptide SuO-Val-Cit-PAB .
2
2
Target:
Research Areas:
2
2 Cited Publications
Cat. No.: HY-P1050
CAS No.: 514200-66-9
Target:
Research Areas:
COG 133 is a fragment of Apolipoprotein E (APOE) peptide. COG 133 competes with the ApoE holoprotein for binding the LDL receptor, with potent anti-inflammatory and neuroprotective effects. COG 133 is also a nAChR antagonist with an IC50 of 445 nM .
2
2 Cited Publications
Cat. No.: HY-P1050A
CAS No.: 2828432-37-5
Target:
Research Areas:
2
Target:
Research Areas:
2
Research Areas:
1
1 Cited Publications
Target:
Research Areas:
NRX-2663 is an enhancer of the interaction between β-catenin, and its cognate E3 ligase, SCF β-TrCP. NRX-2663 enhances the binding of β-catenin peptide for β-TrCP with an EC50 of 22.9 μM and a Kd of 54.8 nM .
1
1
1 Cited Publications
Cat. No.: HY-W591424
CAS No.: 92451-01-9
Synonyms: mPEG2000-SC; mPEG2000-Succinimidyl ester
Target:
Research Areas:
Auristatin E is a cytotoxic microtubule polymerization inhibitor with potent and selective antitumor activity. Auristatin E is a cytotoxin in antibody-drug conjugates (ADC). Auristatin E inhibits cell division by blocking the polymerisation of tubulin, promising for research in B-cell malignancies. Auristatin E, a synthetic analogue of the Dolastatin 10 (HY-15580), is linear peptides comprised of four amino acids .
Cat. No.: HY-13631ES4
Synonyms: MC-GGFG-DXD-d5
Cat. No.: HY-P4121
CAS No.: 1898254-09-5
Target:
Research Areas:
Target:
Research Areas:
Penicillin amidase, E. coli (Immobilized) (PGA) is an amidohydrolase commonly used in industrial biocatalysis. Penicillin amidase, E. coli (Immobilized) serves as a starting material in the synthesis of semi-synthetic penicillins. Penicillin amidase, E. coli (Immobilized) promotes the production of semi-synthetic β-lactam antibiotics, participates in peptide synthesis, and catalyzes the formation of chiral compounds. Penicillin amidase, E. coli (Immobilized) is regulated by temperature and phenylacetic acid in E. coli. In free E. coli, it participates in the assimilation of aromatic compounds as a carbon source. Penicillin amidase, E. coli (Immobilized) is hypothesized to act as a scavenging enzyme for phenylacetyl-containing compounds in microbial metabolism and is associated with bacterial quorum sensing .
Synonyms: BI 1029539; GS-248; OX-MPI
Target:
Vipoglanstat (BI 1029539), a carboxamide, is a potent and selective, non-peptide and orally active small molecular inhibitor of human prostaglandin E synthase 1 (mPGES-1). Vipoglanstat also has anti-inflammatory activity .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
